Weekly paclitaxel in ovarian cancer-the latest success story

Affiliations

A Jain et al. Curr Oncol. 2011 Jan.

. 2011 Jan;18(1):16-7.

doi: 10.3747/co.v18i1.680.

¹ Medical Oncology, Regional Cancer Center, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India, ankitjaindm@gmail.com.

No abstract available

Keywords: Weekly paclitaxel; adjuvant chemotherapy; intraperitoneal chemotherapy; ovarian cancer.

References

1. Markman M, Blessing J, Rubin SC. Phase ii trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;101:436–40. doi: 10.1016/j.ygyno.2005.10.036. - DOI - PubMed
1. Katsumata N, Yasuda M, Takahashi F, et al. on behalf of the Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374:1331–8. doi: 10.1016/S0140-6736(09)61157-0. - DOI - PubMed
1. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358:1663–71. doi: 10.1056/NEJMoa0707056. - DOI - PMC - PubMed
1. Rose PG, Smrekar M, Fusco N. A phase ii trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma. Gynecol Oncol. 2005;96:296–300. doi: 10.1016/j.ygyno.2004.03.046. - DOI - PubMed
1. Bookman MA. Dose-dense chemotherapy in advanced ovarian cancer. Lancet. 2009;374:1303–5. doi: 10.1016/S0140-6736(09)61305-2. - DOI - PubMed